AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Background
Primary resistance and early progression remain major barriers to durable benefit from CD19-directed chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL). Although antigen loss contributes to treatment failure, the pretreatment genomic, malignant-cell, and tumor-microenvironmental states associated with resistance remain incompletely defined. We integrated multi-omic profiling with functional perturbation to identify clinically relevant tumor programs associated with CAR T-cell failure.
Methods
Pretreatment tumors from a prospective institutional cohort of 44 patients with LBCL treated with CD19 CAR T cells were profiled by whole-exome sequencing (WES; 34 patients and 48 longitudinally collected specimens), bulk RNA sequencing (RNA-seq; 23 patients), and single-cell RNA-seq (12 patients). Patients were classified as primary nonresponders (NR), early progressors (progression-free survival [PFS] <90 days), late progressors, or durable responders. Somatic mutations and copy-number alterations (CNAs), transcriptional programs, malignant B-cell clonotypes, and immune-cell states were analyzed across platforms. An external CAR T-cell–treated cohort (n=43) was used for validation. MLLT11 was knocked down in MLLT11-high Karpas-422 cells and overexpressed in MLLT11-low U2932 cells, followed by co-culture with CD19 CAR T cells across multiple effector-to-target ratios and time points.
Results
NR tumors displayed greater chromosomal instability. Pretreatment 1q21.3 amplification was enriched in primary NR compared with durable responders (6/9 [66.7%] vs 2/14 [14.3%]; Fisher exact P=0.0228) and was associated with inferior overall survival. Copy number at the MLLT11 locus correlated with bulk MLLT11 expression (r=0.77; n=18), identifying MLLT11 as a dosage-linked candidate within the amplicon. High MLLT11 expression was associated with shorter PFS in both the institutional bulk cohort (log-rank P=0.0003) and an external dataset (P=0.013).
Single-cell analysis localized MLLT11 predominantly to dominant-clone malignant B cells and identified an MLLT11-high state enriched for cell-cycle and chromatin-remodeling programs, with reduced antigen-presentation and interferon-related signaling. This malignant-cell state co-occurred with an immune-depleted microenvironment characterized by fewer activated/memory CD8 T cells and plasmacytoid dendritic cells, enrichment of terminal-effector CD8 states, and myeloid remodeling. Bulk RNA-seq deconvolution supported these cellular shifts.
Functionally, MLLT11 knockdown in Karpas-422 cells increased susceptibility to CAR T-cell killing, whereas MLLT11 overexpression in U2932 cells increased tumor-cell survival following CAR T-cell exposure across multiple experimental conditions. Knockdown was accompanied by increased surface CD19 and HLA-ABC expression, while overexpression produced context-dependent changes in immune-recognition markers, including reduced HLA-DR.
Conclusions
Integrated genomic, bulk, and single-cell profiling identifies a 1q21.3–MLLT11 program associated with primary resistance and adverse outcomes after CD19 CAR T-cell therapy in LBCL. MLLT11-high dominant malignant B-cell states co-occur with impaired immune-recognition programs and an immune-depleted microenvironment, while bidirectional perturbation functionally links MLLT11 expression to CAR T-cell sensitivity. These findings nominate 1q21.3/MLLT11 as a candidate pretreatment biomarker and functional contributor to CAR T-cell resistance, warranting prospective validation and further mechanistic investigation.